Loading...
NYSE: AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
Market Cap
$145.40B
52w High
$212.71
52w Low
$122.48
P/E
28.29
Volume
1.03M
Outstanding Shares
775.14M
Company profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
CEOPascal Claude Roland Soriot
SectorHealthcare
IndustryDrug Manufacturers - General
Employees94,300
IPO dateMay 12, 1993
Valuation
Forward P/E—
EV/EBITDA8.07
Enterprise value$160B
Stock splits
Feb 2, 20261:2
Jul 27, 20152:1
Apr 8, 19983:1
Profitability & growth
Revenue growth4.11%
Gross margin78.23%▲0.95%vs FY2024
Operating margin23.28%▲26.48%vs FY2024
ROE21.07%▲22.17%vs FY2024
Analyst consensus
RatingBuy
Target price$105.50▼43.76%
20
Buy
15
Hold
6
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 29, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.18
$2.16
Q3FY25
ActualEst.
$2.38
$2.29
Q4FY25
ActualEst.
$2.12
$2.09
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$14.46B
$14.76B
Q3FY25
ActualEst.
$15.19B
$15.42B
Q4FY25
ActualEst.
$15.5B
$14.6B
Q1FY26
Next Est.
—